Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 1/20 | 0.56 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.56 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA2 | P00918 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226705 | 1.00 | CARM1 (0.56) | CARM1PRMT6PRMT8HRH3CA12 | |
| SCHEMBL4569287 | 0.98 | CARM1 (0.58) | CARM1PRMT6PRMT8HRH3CA12 | |
| SCHEMBL13787914 | 0.93 | CARM1 (0.52) | CARM1PRMT6PRMT8HRH3CA12 | |
| SCHEMBL25736046 | 0.90 | CARM1 (0.48) | CARM1PRMT6PRMT8CA12CA1 | |
| SCHEMBL12309176 | 0.86 | HRH3 (0.52) | CARM1PRMT6PRMT8HRH3MAPT | |
| SCHEMBL18568453 | 0.86 | HRH3 (0.52) | CARM1PRMT6PRMT8HRH3MAPT | |
| SCHEMBL16311941 | 0.85 | HRH3 (0.56) | CARM1PRMT6PRMT8HRH3MAPT | |
| SCHEMBL10574951 | 0.85 | CARM1 (0.50) | CARM1PRMT6PRMT8HRH3CA12 | |
| SCHEMBL18782445 | 0.85 | CARM1 (0.50) | CARM1PRMT6PRMT8HRH3CA12 | |
| SCHEMBL8258583 | 0.84 | CARM1 (0.48) | CARM1PRMT6PRMT8HRH3MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136434-B2 | Polyamines, synthesis method thereof and use thereof for the selective elimination of H2S from a gaseous effluent comprising CO2 | IFP Energies Nouvelles (FR) | 2021-10-05 | — | — | US | claimed |
| CN-108602952-B | Novel polyamines, method for their synthesis and their use for the removal of CO from a gas containing atmosphere2Selective removal of H from the gaseous effluent of2Use of S | IFP 新能源公司 | 2021-03-12 | — | — | CN | claimed |
| US-10710021-B2 | Polyamines, synthesis process thereof and use of same for the selective elimination of H2S from a gaseous effluent comprising CO2 | IFP Energies Nouvelles (FR) | 2020-07-14 | — | — | US | claimed |
| US-20200148824-A1 | NOVEL POLYAMINES, SYNTHESIS METHOD THEREOF AND USE THEREOF FOR THE SELECTIVE ELIMINATION OF H2S FROM A GASEOUS EFFLUENT COMPRISING CO2 | IFP Energies Nouvelles (FR) | 2020-05-14 | — | — | US | claimed |
| EP-3645605-A1 | NOVEL POLYAMINES, SYNTHESIS METHOD THEREOF AND USE THEREOF FOR THE SELECTIVE ELEMINATION OF H2S FROM A GASEOUS EFFLUENT COMPRISING C02 | IFP Energies nouvelles (FR) | 2020-05-06 | — | — | EP | claimed |
| EP-3397671-B1 | NOVEL POLYAMINES, SYNTHESIS PROCESS THEREOF AND USE OF SAME FOR THE SELECTIVE ELIMINATION OF H2S FROM A GASEOUS EFFLUENT COMPRISING CO2 | IFP ENERGIES NOW (FR) | 2020-02-12 | — | — | EP | claimed |
| US-20180369743-A1 | NOVEL POLYAMINES, SYNTHESIS PROCESS THEREOF AND USE OF SAME FOR THE SELECTIVE ELIMINATION OF H2S FROM A GASEOUS EFFLUENT COMPRISING CO2 | IFP Energies Nouvelles (FR) | 2018-12-27 | — | — | US | claimed |
| EP-3397671-A1 | NOVEL POLYAMINES, SYNTHESIS PROCESS THEREOF AND USE OF SAME FOR THE SELECTIVE ELIMINATION OF H2S FROM A GASEOUS EFFLUENT COMPRISING CO2 | IFP Energies nouvelles (FR) | 2018-11-07 | — | — | EP | claimed |
| CN-108602952-A | Novel polyamines, a process for their synthesis and their use for the selective removal of H2S from gaseous effluents containing CO2 | IFP 新能源公司 | 2018-09-28 | — | — | CN | claimed |
| US-20130011314-A1 | METHOD OF REMOVING ACID COMPOUNDS FROM A GASEOUS EFFLUENT WITH AN ABSORBENT SOLUTION BASED ON I, II/III DIAMINES | IFP Energies Nouvelles (FR) | 2013-01-10 | — | — | US | claimed |
| WO-2024123633-A1 | LIPID NANOPARTICLE COMPOSITIONS AND USES THEREOF | RECODE THERAPEUTICS, INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | ARROMAX PHARMATECH CO., LTD. (CN) | 2024-01-18 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | UNIV YALE (US) | 2023-12-14 | — | — | US | disclosed |
| US-4146558-A | Azo dyestuff intermediate nitro- or aminobenzenes ring-substituted by a quaternized amine alkyl or amino-alkoxy group | STERLING DRUG INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4103092-A | Water-soluble quaternary ammonium non-heterocyclic azo dyestuffs | STERLING DRUG INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4065500-A | Water-soluble quaternary ammonium azo dyestuffs | STERLING DRUG INC. (US) | 1977-12-27 | — | — | US | disclosed |
| US-3996282-A | Water-soluble quaternary ammonium dyestuffs | STERLING DRUG INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3935182-A | Water-soluble quaternary ammonium heterocyclic azo dyestuffs | STERLING DRUG INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | CARM1 4298/4885PRMT6 3040/4885PRMT8 2620/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | CARM1 3846/4885PRMT6 2289/4885PRMT8 2700/4885 |
| US-20240018150-A1 | SMALL MOLECULAR INHIBITOR AGAINST BTK AND/OR BTK C481S AND USE THEREOF | BTK, SYK, LCK | CARM1 1198/4885PRMT6 2081/4885PRMT8 2199/4885 |
| US-20230399303-A1 | Macrophage Migration Inhibitory Factor Inhibitors, and Methods of Making and Using Same | MIF, MMP12, METAP1 | CARM1 1063/4885PRMT6 217/4885PRMT8 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.